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Xanthine oxidase inhibitorsHyperuricemia has long been established as the major etiologic factor in gout. Alongside with an inﬂammatory
state triggered by urate crystal deposition in the joints, hyperuricemia displayed additional pathophysiological
consequences leading to tissue inﬂammation mainly in the vascular wall. Thus, therapeutic strategies used to
treat hyperuricemia in the past decades have often been focused on limiting acute episodes. Recently, evidence
has been accumulated suggesting that chronic urate deposition requires a correct treatment not limited to
acute episodes based on the modulation of the activity of key enzymes involved in metabolism and excretion
of urate including xanthine oxidoreductase (XO) and URAT1. The present review article will try to summarize
the most recent evidences on the efﬁcacy of XO inhibitors and uricosuric compounds in lowering uric acid levels
in both the bloodstream and peripheral tissues. In particular, we will focus on the effect of novel XO inhibitors in
counteracting uric acid overproduction. On the other hand, the effect of lowering uric acid levels via XO inhibition
will be correlated with attenuation oxidative stress which leads to endothelial dysfunction thereby contributing
to the pathophysiology of diabetes, hypertension, arteriosclerosis, and chronic heart failure. Hence, scavenging
and prevention of theXOgenerated oxygen radical accumulation emerge as an intriguing novel treatment option
to counteract uric acid-induced tissue damages.359,
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Hyperuricemia and gout are pathological conditions characterized
by overproduction or under-excretion of uric acid, a product of purine
catabolism physiologically excreted in the urine. Both conditions are
often associated with chronic diseases such as hypertension, diabetes
mellitus, metabolic syndrome, renal and cardiovascular diseases.
As a consequence, uricemia control is fundamental, as well as mon-
itoring of uric acid levels over time. European Guidelines suggest serum
uric acid levels ≤6 mg/dL in people having chronic hyperuricemia with
urate deposition. In this context, non-pharmacological therapy (diet
poor in purine-rich food, sugars, alcohol and rich in vegetables and
water intake) is critical; however, if it is not effective in reducing uric
acid levels, then pharmacological therapy is required [1].
The most common clinical features of hyperuricemia are accompa-
nied by crystallization and deposition of uric acid in joints and
surrounding tissues, however the precise mechanism for uric acid-
induced tissue injury remains unclear.PON03PE_00078_1 and
afety & Health (IRC-FSH),
“Salvatore Venuta”, Viale
td. This is an open access articlIt has been hypothesized that uric acid (UA) overproduction can
trigger oxidative stress and that xanthine oxidoreductase (XO), the en-
zyme responsible for urate formation, may play a critical role in this
context. In addition, impaired xanthine oxidase activity appears in-
volved in the onset of cardiovascular diseases associated with hyperuri-
cemia. XO inhibitors are potentially effective drugs to control these uric
acid-related dysfunctions. Due to the limitations of currently available
XO inhibitory drugs, the development of new ones with more potency,
different pharmacological mechanisms, and less toxicity is an active
ﬁeld of research [2].
The aim of this review is to highlight new therapeutic strategies
aimed at antagonizing adverse effects of current drugs used for hyper-
uricemia treatment and tominimize at the same time the risk of cardio-
vascular diseases.
2. Uric acid: physiology and pharmacology
2.1. Physiology
Uric acid is the ﬁnal product of purine nucleotide catabolism which
can be modulated by different factors such as diet or drugs used for
the treatment of multiple cardiovascular risk factors or cardiovascular
comorbidities.
Hypoxanthine and xanthine are the intermediate products of this ca-
tabolism. Xanthine oxidoreductase catalyzes the ﬁnal two reactions in
the biochemical chain that leads to uric acid formation: the conversione under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tered at the glomerulus, but up to 90% of ﬁltered urate is reabsorbed.
The main transporters responsible for tubular reabsorption are URAT1
and GLUT9 [3].
In most mammals, uricase (urate oxidase), an enzyme very effective
in lowering uric acid levels, oxidizes uric acid to allantoin which is high-
ly soluble in water and excreted unchanged in the urine. Unfortunately,
urate oxidase is not a functional human enzyme and, as a result, humans
can develop hyperuricemia. Consequently, uric acid crystals can accu-
mulate in human tissues and in the urinary tract, causing chronic
hyperuricemia-related diseases [1].
2.2. Pharmacology
2.2.1. Treatment of acute gout
Therapeutic strategies used to treat hyperuricemia are often focused
on limiting acute episodes characterized by an inﬂammatory response
of cells triggered by urate crystal deposition. These events are
counteracted using nonsteroidal antinﬂammatory drugs (NSAIDs),
colchicine or glucocorticoids which act through different mechanisms.
In particular, NSAIDs' effect is due to the inhibition of prostaglandin
generation by up-regulated COX-2, recognized as the most important
event in the stimulation of inﬂammatory responses which characterize
gouty arthritis attacks [4].
In vitro studies have shown that high concentrations of colchicine
suppress inﬂammation by blocking IL-1beta processing in monocytes
stimulated by monosodium urate (MSU). Moreover, it down-regulates
tyrosine kinases and phospholipases in neutrophils, inhibiting chemo-
taxis, superoxide anion production, adhesion to cellular substrata, and
mobilization and release of lysosomal enzymes during phagocytosis.
Further evidence shows that fewer doses of colchicine are also able to
alter the expression of endothelial adhesion molecules (E-selectin) on
cells required for the recruitment of neutrophils [5]. Other actions are
probably due to the capacity of colchicine to disrupt microtubules.
However, its interaction with microtubules can cause accumulation of
lysosomes and autophagic vacuoles in the cytoskeleton, resulting in
pathologic alterations in skeletal muscle and induction of signiﬁcant ax-
onal neuropathy. These adverse consequences may manifest as myopa-
thy (e.g. rhabdomyolysis), neuropathy, or bonemarrow suppression [6].
Glucocorticoids have many well-described anti-inﬂammatory ef-
fects mediated by binding with glucocorticoid receptors, which are lo-
calized in the cytoplasm of target cells found in almost all tissues in
the human body.
In acute gouty arthritis, the most notable anti-inﬂammatory action
of glucocorticoids depends on the capacity for preventing activation of
pro-inﬂammatory transcription factors such as NFκB and activating
protein-1 (AP-1). In particular, glucocorticoids increase the expression
of the inhibitor of κB (IκB), the cytoplasmic chaperone that prevents
translocation of NFκB to the nucleus, inhibiting IL-1beta production. In
addition to NFκB and AP-1, other transcription factors are negatively
regulated by the glucocorticoid receptors and target genes include
those encoding for a broad range of inﬂammatory cytokines, enzymes,
receptors, and adhesion molecules such as IL-1beta, COX-2, E-selectin,
and TNF-alpha [4].
Despite themultiplemechanisms of action of NSAIDs, colchicine and
glucocorticoids, none of these options are universally effective in
counteracting gout-induced inﬂammation or completely safe. Indeed,
NSAIDs are chosen for patients without comorbid illnesses, but they
are inappropriate for patients with renal impairment, congestive cardi-
ac failure and peptic ulcer disease and in those treated with anti-
coagulants. Moreover, the use of very high doses of NSAIDs for
patients with acute gout can induce gastric toxicity, and a reduced
creatinine clearance, more relevant in patients affected by renal
impairment [7].
Corticosteroids are also effective but they may interfere with blood
pressure or glucose control.Colchicine is used for patients who cannot be treatedwith NSAIDs or
corticosteroids. However, it has a narrow therapeutic index.
As consequence, new therapies have been developed to better man-
age acute gout. Among them, a growing interest is focused on biological
therapies aimed at counteracting the inﬂammatory effect of IL-1beta,
considered a key mediator in the pathogenesis of gout, and triggered
by MSU crystals. In particular, an open-labeled study showed that
anakinra, an IL-1 receptor antagonist, resulted in rapid and complete
pain relief without causing any side-effects in patients who failed con-
ventional treatments such as NSAIDs, colchicine or corticosteroids.
Rilonacept (a soluble IL-1 receptor that binds to IL-1 to prevent the bind-
ing with its original receptor) and canakinumab (a monoclonal antibody
against IL-1beta) also resulted asmore effective than allopurinol and cor-
ticosteroids [8].
All these drugs can represent valid alternative treatments for those
patients in whom cardiovascular, renal and gastrointestinal comorbidi-
ty would preclude the use of NSAIDs, corticosteroids and colchicine.
Another recent advance in the management of acute gout regards
the use of lower doses of colchicine. Indeed, it has been observed that
lower doses of colchicine were as effective as higher doses in relieving
pain showing a reduction of side-effects [9].
2.2.2. Long-term management of hyperuricemia
Despite of the progresses in acute gout therapy, it is also evident that
urate deposition is a chronic disease requiring a correct treatment not
limited to acute episodes.
In the development of gout, the ﬁrst step is characterized by urate
saturation in serum.Over the saturation level, formation ofMSU crystals
occurs with a consequent interaction with the inﬂammatory system.
Drugs given for long-term prophylaxis act at the ﬁrst step for reducing
serum urate levels.
Currently, the long-term management of hyperuricemia is aimed at
modulating the activity of key enzymes involved in themetabolism and
excretion of urate as XO and URAT1. They are divided in twomain clas-
ses: uricostatic drugs (e.g. allopurinol), which reduce uric acid produc-
tion through competitive inhibition of xanthine oxidase and uricosuric
drugs (e.g. sulphinpyrazone, probeneceid and benzbromarone), which
increase urinary uric acid excretion by blocking renal tubular re-
absorption of urate [8].
Primary urate-lowering therapy is often initiatedwith a XO inhibitor
such as allopurinol or febuxostat. Allopurinol is generally a safe drug,
but ~2% of patients develop hypersensitivity reactions, which can some-
times be severe and fatal with a mortality rate of ~20%. Moreover, allo-
purinol can have both dose-related (e.g., gastrointestinal intolerance
and rashes) and idiosyncratic side effects. This occurs especially
among patients with renal impairment, inwhom the dose of allopurinol
has not been appropriately reduced. On the other hand, lower doses
of allopurinol used in these patients do not adequately control gout
[10,11].
Febuxostat is a non-purine, xanthine oxidase inhibitor with a chem-
ical structure different from allopurinol. It was recently approved by the
National Institute for Health and Care Excellence (NICE) for use in pa-
tients intolerant to allopurinol and its antihyperuricemic efﬁcacy has
been shown at 80 to 120 mg/day. This lower dosage in comparison
with the “standard dosage” of allopurinol (300 mg/day) might be due
to its selectivity toward xanthine oxidase in the purine/pyrirmidine
metabolic pathway. The most commonly reported adverse drug reac-
tions are liver function abnormalities, diarrhea, headache, nausea, and
rash. Febuxostat appears less toxic than allopurinol and in patients
with mild to moderate renal impairment, dose adjustments are not
needed, as it ismainlymetabolized in the liver.Moreover, its pharmaco-
kinetics and pharmacodynamics are not signiﬁcantly altered in patients
with moderate hepatic impairment [8].
Despite the beneﬁcial effects of allopurinol and febuxostat in gout
therapy, the number of patients achieving serum urate levels b6 mg/dL
(b0.35 mmol/L) is in the range of 20–40% for allopurinol and 45–67%
Table 1
Pharmacology of hyperuricemia.
Mechanism
Treatment of acute gout
Drugs
NSAIDs COX-2 inhibitors
Colchicine Inhibition of IL-1beta processing
Down-regulation of tyrosine kinases and phospholipases in
neutrophils
Inhibition of chemotaxis, superoxide anion production,
adhesion to cellular substrata, mobilization and release of
lysosomal enzymes
Disruption of microtubules
Corticosteroids Prevention of pro-inﬂammatory transcription factor activation
with inhibition of inﬂammatory cytokines, enzymes, receptors,
and adhesion molecules
Drugs in development
Anakinra IL-1 receptor antagonist
Rilonacept Soluble IL-1 receptor
Canakinumab Monoclonal anti-IL-1beta antibody
Long-term management of hyperuricemia
Drugs
Allopurinol XO inhibitor
Febuxostat XO inhibitor
Sulphinpyrazone URAT1 inhibitor
Probenecid URAT1 inhibitor
Benzbromarone URAT1 inhibitor
Drugs in development
Lesinurad URAT1 inhibitor
Arhalofenate URAT1 inhibitor
Levotoﬁsopam URAT1 inhibitor
RDEA3170 URAT1 inhibitor
BCX4208 Purine nucleoside phosphorylase inhibitor
Pegloticase Pegylated uricase
Pegadricase Pegylated uricase
DHNB XO inhibitor
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therapies [3,8].
A potential drug under preclinical study for the treatment of hyperuri-
cemia by inhibiting XO activity is 3,4-dihydroxy-5-nitrobenzaldehyde
(DHNB), a derivative of natural protocatechuic aldehyde. DHNB inhibits
XO in a time-dependent manner similarly to allopurinol. In particular,
DHNB displays potent mixed-type inhibition of the activity of XO, and
shows an additive effectwith allopurinol at low concentrations. DHNB in-
teractswith themolybdenumcenter ofXOand is able to directly scavenge
free radicals [12].
Uricosuric drugs are an option in patients who are intolerant to
allopurinol. Among them, probenecid, the older URAT1 inhibitor, is
still available in some countries, but is contraindicated and ineffective
in patients with renal calculi and renal impairment respectively,
whereas benzbromarone has largely been withdrawn because of liver
toxicity [3].
Other uricosuric drugs in clinical development aremainly URAT1 in-
hibitors such as lesinurad, arhalofenate, levotoﬁsopam and RDEA3170.
Lesinurad can achieve target serum urate levels when given with allo-
purinol or febuxostat in 60–100% of the patients [13–15].
Further drugs acting through different mechanisms are the non-
absorbable phosphate binder sevelamer that increases gastrointestinal
elimination, BCX4208, an inhibitor of purine nucleotide phosphorylase
and the pegylated uricases (pegloticase and pegadricase) that reduce
urate levels by increasing its metabolism [13].
Pegloticase is approved for patients refractory to conventional treat-
ments (mainly used in severe tophaceous gout) and pegadricase has
been in Phase I trial. Pegloticase has been shown to rapidly reduce
serum urate levels so the majority of patients experience acute gout
ﬂares, and hence, pegloticase is co-prescribed with colchicine, NSAIDs
or corticosteroids [3,8].
Pegloticase can only be used over a short period (~3–6 months) be-
cause many patients often develop anti-pegloticase antibodies that can
reduce its efﬁcacy. Consequently, pegloticase may be used for a short
time in patients refractory to current prophylactic treatments, before
the administration of other drugs as allopurinol or febuxostat. This
would allow the management of hyperuricemia for a longer time [8].
Therefore, all these last emerging treatments are aimed at improving ef-
ﬁcacy and reducing the side effects of traditional therapies (Table 1).
3. Chronic hyperuricemia and cardiovascular disease
In recent years, a large body of evidence suggests that hyperuricemia
may play a role in the development and pathogenesis of a number of
metabolic, hemodynamic, and systemic pathologic diseases, including
metabolic syndrome, hypertension, stroke, and atherosclerosis.
The mechanisms underlying the role of uric acid in disorders other
than gout are not well established but recent investigations point to-
ward oxidative stress as the major pathophysiological event common
to systemic diseases mentioned above. Uric acid has both pro-oxidant
and antioxidant activity. As an antioxidant, it chelates metals and scav-
enges oxygen radicals. As a pro-oxidant, it oxidizes lipids, reduces nitric
oxide availability in endothelial cells, and increases reactive oxygen spe-
cies. As a result high levels of serum uric acid cause inﬂammationwhich
would be expected to disrupt reverse cholesterol transport causing an
increase of cardiovascular risk [16].
Reactive oxygen species (ROS) overproduction may be also caused
by the enhancement of XO expression and activity. This hypothesis is
supported by clear evidence showing that XO is involved in various
forms of ischemic and vascular injuries, inﬂammatory diseases, and
chronic heart failure [17–19].
As mentioned above, xanthine oxidoreductase catalyzes the ﬁnal
two reactions in the biochemical chain that leads to uric acid formation.
The second step of this process is responsible for the superoxide anion
radical and/or hydrogenperoxideH2O2 formation. XO is therefore a crit-
ical source of ROS and, in particular, of superoxide which can rapidlyreact with NO to form cytotoxic oxidant peroxynitrite (ONOO−).
ONOO− production togetherwith the pro-oxidant properties of UA con-
tributes to the decrease of nitric oxide levels leading to endothelial dys-
function and contributing to atherosclerosis and cardiovascular diseases
[16,20]. These mechanisms suggest that there is a need for novel, more
speciﬁc antioxidant and anti-inﬂammatory approaches aimed at
preventing ROS formation by targetingmolecular pathways directly in-
volved in ROS generation (e.g. XO) and counteracting overt oxidative
stress (Fig. 1).4. Old and new XO inhibitors in the management of cardiovascular
diseases
4.1. Allopurinol and oxypurinol
Recent data indicate that XO plays an important role in various
forms of ischemic and other types of tissue and vascular injuries, inﬂam-
matory diseases, and chronic heart failure. It has been demonstrated
that XO inhibitors allopurinol and oxypurinol, the active metabolite of
allopurinol, have beneﬁcial effects in the treatment of these conditions.
Indeed, administration of allopurinol or oxypurinol has positive effects
on reperfusion-induced arrhythmias and infarct size in different animal
models. The cardioprotective effect of allopurinol or oxypurinol, in re-
sponse to brief periods of ischemia, is probably due to the inhibition of
XO activity but also to non-selective actions of these compounds that
are able to act as free radical scavengers, copper chelators and inhibitors
of lipid peroxidation [16].
Recent evidence reveals a role for the xanthine oxidase metabolic
pathway also in the pathophysiology of chronic heart failure (CHF). In
particular, several studies show that xanthine oxidase inhibition in-
creases contractile capacity due to a calcium (Ca2+) sensitizing
Fig. 1. Uric acid induces endothelial dysfunction enhancing the risk of cardiovascular disease development. ROS: reactive oxygen species; RNS: reactive nitrogen species; LPO: lipid per-
oxidation; oxLDL: oxidized low density lipoproteins; SMCs: smooth muscle cells.
Modiﬁed from [20].
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oxygen consumption [21].
In addition, it has beendemonstrated that the cardioprotective effect
of allopurinol and ascorbate in dogs with heart failure can be prevented
by nitric-oxide synthase (NOS) inhibition, suggesting that XO-derived
superoxide may interfere with NO regulation of myocardial energetics
[22]. Interestingly, the deﬁciency of neuronal NOS but not endothelial
NOS was associated with an enhancement in XO mediated superoxide
production which induced a contractile depression of cardiomyocytes.
Superoxide-mediated cardiomyocyte dysfunction was prevented by
allopurinol, suggesting that nNOS, inhibiting XO activity, suppresses
XO-dependent superoxide production [16].
XO-derived superoxide production farther contributes to the devel-
opment of diabetic cardiomyopathy, and XO inhibition with allopurinol
improves diabetes-induced cardiac dysfunction by decreasing oxida-
tive/nitrosative stress. As a consequence, allopurinol inhibits activation
of downstream effector pathways of oxidative stress and ﬁbrosis, sug-
gesting its multiple possible beneﬁts in the treatment of diabetes [23].4.2. Febuxostat
Febuxostat is able to inhibit both oxidized and reduced forms of the
enzyme, preventingROS andONOO− formation aswell as inﬂammation
promoted by oxidative stress.
The marked protection afforded against vascular inﬂammation
might be due to a more potent XO inhibitory effect than allopurinol
caused by its binding to both oxidized and reduced forms of XO; more-
over, it blocks substrate access to the active site. Indeed, the administra-
tion of febuxostat is able to reduce nitro-oxidative stress highlighted by
nitrotyrosine formation, lipid peroxidation and over-expression of var-
ious inﬂammation-related molecules promoting the onset and the pro-
gression of the inﬂammatory state [20,24]. In addition, febuxostat
inhibits circulating XO, preventing its binding to the surface of endothe-
lial cells by glycosaminoglycans (GAGs), a process involved in the path-
ogenesis of endothelial injury [25].This novel drug is also beneﬁcial in the CHF aswell as during the ini-
tial phase of left ventricular remodeling and cardiac functional deterio-
ration after myocardial infarction. Besides the effect of febuxostat on
ventricular dysfunction and myocardial hypertrophy, it also limits ven-
tricular collagen synthesis, preventing ﬁbrosis. The cardiac protective
effect may also be associated with a reduced oxidative stress. Despite
this evidence, the role of febuxostat in humans requires further investi-
gation [20].5. Natural antioxidants and prevention of hyperuricemia-induced
CVR
It has been demonstrated that plant-derived antioxidants have anti-
gout potential. In in vitro studies, ﬂavonoids, alkaloids, essential oils,
phenolic compounds, tannins, iridoid glucosides, and coumarins show
the potential of anti-gout effects by their XO inhibitory action. Phenolic
compounds and ﬂavonoids inhibit UA production, showing uricosuric
anti-inﬂammatory effects.Moreover, recent evidence has demonstrated
a therapeutic potential for natural polyphenols such as bergamot de-
rived polyphenols, alone or in combination therapy, to counteract detri-
mental effects of oxidative stress which characterize pathological states
associated with the main cardiovascular risk factors. This dual effect of
polyphenols, XO inhibitors and free radical scavengers respectively,
suggests new therapeutic perspectives to prevent hyperuricemia, UA-
induced oxidative stress, inﬂammation and tissue injury. Moreover, it
will be possible to hypothesize alternative therapeutic strategies based
on the use of lowdoses of XO inhibitors in combinationwith natural an-
tioxidants to minimize their side effects [26–30].Conﬂict of interest
The authors report no relationships that could be construed as a
conﬂict of interest.
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